The effect of treatment advances on the mortality results of breast cancer screening trials: A microsimulation model

Annals of Internal Medicine

Volumn 164, Issue 4, 2016, Pages 236-243

  Birnbaum, Jeanette ^a   Gadi, Vijayakrishna K ^a   Markowitz, Elan ^b   Etzioni, Ruth ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; COMPUTER SIMULATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK REDUCTION; SYSTEMIC THERAPY; BREAST NEOPLASMS; CANCER STAGING; EARLY CANCER DIAGNOSIS; EPIDEMIOLOGY; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; MORTALITY; UNITED STATES;

AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMPUTER SIMULATION; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; UNITED STATES;

EID: 84958794252     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-0754     Document Type: Article

References (43)

1. Kolata G. Considering when it might be best not to know about cancer. The New York Times. 29 October 2011. Accessed at www.nytimes.com/2011/10/30/health/cancer-screening-may-be-more-popular-than-useful.html on 14 August 2015.
2. Woolf SH, Harris R. The harms of screening: new attention to an old concern. JAMA. 2012;307:565-6. [PMID: 22318274] doi:10.1001/jama.2012.100
3. Agency for Healthcare Research and Quality. U.S. Preventive Services Task Force Procedural Manual. AHRQ publication no. 08-05118-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2008. Accessed at www.uspreventiveservicestaskforce.org/Home/GetFile/6/7/procmanual/pdf on 14 August 2015.
4. Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120-34. [PMID: 22801674] doi:10.7326/0003-4819-157-2-201207170-00459
5. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348:g366. [PMID: 24519768] doi:10.1136/bmj.g366
6. Berry DA. Breast cancer screening: controversy of impact. Breast. 2013;22 Suppl 2:S73-6. [PMID: 24074796] doi:10.1016/j.breast.2013.07.013
7. Etzioni R, Gulati R, Cooperberg MR, Penson DM, Weiss NS, Thompson IM. Limitations of basing screening policies on screening trials: the US Preventive Services Task Force and prostate cancer screening. Med Care. 2013;51:295-300. [PMID: 23269114] doi:10.1097/MLR.0b013e31827da979
8. Marmot MG. Sorting through the arguments on breast screening. JAMA. 2013;309:2553-4. [PMID: 23722915] doi:10.1001/jama.2013.6822
9. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013;6:CD001877. [PMID: 23737396] doi:10.1002/14651858.CD001877.pub5
10. Jü ni P, Zwahlen M. It is time to initiate another breast cancer screening trial. Ann Intern Med. 2014;160:864-6. [PMID: 24711124] doi:10.7326/M14-0569
11. Biller-Andorno N, Jüni P. Abolishing mammography screening programs? A view from the Swiss Medical Board. N Engl J Med. 2014;370:1965-7. [PMID: 24738641] doi:10.1056/NEJMp1401875
12. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet. 2012;380:1778-86. [PMID: 23117178] doi:10.1016/S0140-6736(12)61611-0
13. Sledge GW, Mamounas EP, Hortobagyi GN, Burstein HJ, Goodwin PJ, Wolff AC. Past, present, and future challenges in breast cancer treatment. J Clin Oncol. 2014;32:1979-86. [PMID: 24888802] doi: 10.1200/JCO.2014.55.4139
14. Harris R. Screening is only part of the answer to breast cancer. Ann Intern Med. 2014;160:861-3. [PMID: 24711098] doi:10.7326/M14-0616
15. Kalager M, Adami HO, Bretthauer M. Too much mammography [Editorial]. BMJ.2014;348:g1403.[PMID: 24519765] doi:10.1136/bmj.g1403
16. U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;151:716-26. [PMID: 19920272] doi:10.7326/0003-4819-151-10-200911170-00008
17. Smith RA. The value of modern mammography screening in the control of breast cancer: understanding the underpinnings of the current debates. Cancer Epidemiol Biomarkers Prev. 2014;23:1139-46. [PMID: 24991021] doi:10.1158/1055-9965.EPI-13-0946
18. Elmore JG, Harris RP. The harms and benefits of modern screening mammography [Editorial]. BMJ. 2014;348:g3824. [PMID: 24938686] doi:10.1136/bmj.g3824
19. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al; Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784-92. [PMID: 16251534]
20. The Comprehensive R Archive Network. R. Accessed at https://cran.r-project.org on 14 August 2015.
21. National Cancer Institute. Surveillance, Epidemiology and End Results Program SEER∗Stat software. Accessed at http://seer.cancer.gov/seerstat on 14 August 2015.
22. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5:845-56. [PMID: 16239904]
23. Autier P, Hé ry C, Haukka J, Boniol M, Byrnes G. Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening. J Clin Oncol. 2009;27:5919-23. [PMID: 19884547] doi:10.1200/JCO.2009.22.7041
24. Wilmoth JR. The Berkeley Mortality Database. 2005. Accessed at www.demog.berkeley.edu/~bmd/index.html on 14 August 2015.
25. Wever EM, Draisma G, Heijnsdijk EA, de Koning HJ. How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screening. Med Decis Making. 2011;31:550-8. [PMID: 21406620] doi:10.1177/0272989X10396717
26. Feuer EJ, Mariotto A, Merrill R. Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality rates. Cancer. 2002;95:870-80. [PMID: 12209732]
27. Mariotto AB, Feuer EJ, Harlan LC, Abrams J. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. J Natl Cancer Inst Monogr. 2006:7-15. [PMID: 17032888]
28. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771-84. [PMID: 21802721] doi:10.1016/S0140-6736(11)60993-8
29. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100, 000 women in 123 randomised trials. Lancet. 2012;379:432-44. [PMID: 22152853] doi:10.1016/S0140-6736(11)61625-5
30. Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L, et al. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2014;6:CD006242. [PMID: 24919460] doi:10.1002/14651858.CD006242.pub2
31. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, et al. Trastuzumab containing regimens for early breast cancer. Co-chrane Database Syst Rev. 2012;4:CD006243. [PMID: 22513938] doi: 10.1002/14651858.CD006243.pub2
32. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aroma-tase inhibitors versus tamoxifen. J Clin Oncol. 2010;28:509-18. [PMID: 19949017] doi:10.1200/JCO.2009.23.1274
33. National Cancer Institute. DevCan-Probability of Developing or Dying of Cancer. Bethesda, MD: National Cancer Institute; 2015. Accessed at http://surveillance.cancer.gov/devcan on 14 August 2015.
34. Fitzpatrick-Lewis D, Hodgson N, Ciliska D, Peirson L, Gauld M, Liu YY; Canadian Task Force on Preventive Health Care. Breast Cancer-Systematic Review. Accessed at http://canadiantaskforce.ca/ctfphc-guidelines/2011-breast-cancer/systematic-review on 14 August 2015.
35. Ong MS, Mandl KD. National expenditure for false-positive mam-mograms and breast cancer overdiagnoses estimated at $4 billion a year. Health Aff (Millwood). 2015;34:576-83. [PMID: 25847639] doi: 10.1377/hlthaff.2014.1087
36. Bleyer A, Welch HG. Effect of three decades of screening mam-mography on breast-cancer incidence. N Engl J Med. 2012;367: 1998-2005. [PMID: 23171096] doi:10.1056/NEJMoa1206809
37. Etzioni R, Xia J, Hubbard R, Weiss NS, Gulati R. A reality check for overdiagnosis estimates associated with breast cancer screening. J Natl Cancer Inst. 2014;106. [PMID: 25362701] doi:10.1093/jnci/dju315
38. Etzioni R, Gulati R, Mallinger L, Mandelblatt J. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Intern Med. 2013;158:831-8. [PMID: 23732716] doi:10.7326/0003-4819-158-11-201306040-00008
39. Kalia M. Personalized oncology: recent advances and future challenges. Metabolism. 2013;62 Suppl 1:S11-4. [PMID: 22999010] doi: 10.1016/j.metabol.2012.08.016
40. Chung C, Christianson M. Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation. J Oncol Pharm Pract. 2014;20:11-28. [PMID: 23493335] doi:10.1177/1078155212474047
41. Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control. 2010;17:173-6. [PMID: 20664514]
42. Chuang SL, Chen SL, Yu CP, Chang KJ, Yen AM, Chiu SY, et al. Using tumor phenotype, histological tumor distribution, and mam-mographic appearance to explain the survival differences between screen-detected and clinically detected breast cancers. APMIS. 2014;122:699-707. [PMID: 25046200] doi:10.1111/apm.12294
43. Albain KS, Paik S, van't Veer L. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using mul-tigene assays. Breast. 2009;18 Suppl 3:S141-5. [PMID: 19914534] doi:10.1016/S0960-9776(09)70290-5